Radioimaging of Melanoma and CEA Secreting Tumours by Monoclonal Antibodies Performed by Different Routes of Administration

  • Pietro Riva
Part of the NATO ASI Series book series (NSSA, volume 152)


Alternative routes of administration of radiolabelled antitumor monoclonal antibodies were investigated in order to try to overcome some of the limitations of the immunoscintigraphic method observed by using the intravenous route of administration. Such limitations are: a) the high vascular background due to circulating radiolabelled antibodies and possibly to circulating immunocomplexes; b) the high accumulation of radioactivity in liver, spleen and bone marrow, due to nonspecific uptake of antibodies and immunocomplexes, and possibly of degradation products which develop in vivo after the injection; and c) the catabolic degradation of monoclonal antibodies with consequent release of free isotopes that are picked up by their respective critical organs — thyroid, salivary glands, stomach, liver, bone marrow, etc. All these phenomena give rise to a lowering of the signal coming from the target tumor which cannot be easily differentiated from the surrounding tissues. We are then forced in some instances to use dual tracer subtraction techniques, which are particularly useful when I-131 is employed as a label.


Radiolabelled Antibody Label Monoclonal Antibody Artificial Ascites Imperial Cancer Research Fund Intrapleural Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Buraggi, G.L., Callegaro, L., Turrin, A., Cascinelli, N., Attili, A., Emanuelli, H., Gasparini, M., Deleide, G., Plassio, G., Dovis, M.,Mariani, G., Natali, P. G., Scassellati, G. A., Rosa, U., and Ferrone, S., 1984a, Immunoscintigraphy with 123-I, 99m-Tc and 111-In-labelled F(ab′)2 fragments of monoclonal antibodies to human high molecular weight-melanoma associated antigen (HMW-MAA). J. Nucl. Med. All. Sci., 28:283.Google Scholar
  2. Buraggi, G.L., Callegaro, L., Turrin, A., Gennari, L., Bombardieri, E., Gasparini, M., Mariani, G., Doci, R., Regalia, E., and Seregni, E., 1984b, Immunoscintigraphy of colorectal carcinoma: remarks about an ongoing clinical trial, in: “Nuclear Medicine in Research and Practice”, Schattauer Verlag, Stuttgart.Google Scholar
  3. Buraggi, G.L., Callegaro, L., Mariani, G., Turrin, A., Cascinelli, N., Attili, A., Bombardieri, E., Terno, G., Plassio, G., Dovis, M., Mazzuca, N., Natali, P.G., Scassellati, G.A., Rosa, U., and Ferrone, S., 1985a, Imaging with 131-I-labelled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res., 45:3378.PubMedGoogle Scholar
  4. Buraggi, G.L., Callegaro, L., Turrin, A., Bombardieri, E., Gennari, L., Mariani, G., Ragalia, E., Doci, R., Gasparini, M., Seregni, E., 1985b, Immunoscintigraphy of colorectal carcinoma with an anti-CEA monoclonal antibody, J. Nucl. Med. All. Sci., 29:35.Google Scholar
  5. Colcher, D., Esteban, J., Carrasquillo, J.A., Sugarbaker, P., Reynolds, J.C., Bryant, G., Larson, S.M, and Schlom, J., 1986, Comparison of route of administration of radiolabeled monoclonal antibodies in patients with colorectal cancer, J. Nucl. Med., 27:902.Google Scholar
  6. Epenetos, A.A., 1985, Clinical results with regional antibody-guided irradiation, Application of Monoclonal Antibodies in Clinical Oncology, May, 1985 (Abstract).Google Scholar
  7. Epenetos, A.A., Courtenay-Luck, N., Pickering, P., Hooker, G., Durbin, H., Lavender, J.P., and McKenzie, C.G., 1985, Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen, Br. Med. J., 290:1463.CrossRefGoogle Scholar
  8. Epenetos, A.A., 1986, Intraperitoneal therapy of ovarian cancer, International Conference on Monoclonal Antibody Immunoconjugates for Cancer, UCSD Cancer Center, San Diego, Ca., March 1986 (Abstract).Google Scholar
  9. Epenetos, A.A., Rampling, R., Babentulla, A., Hooker, G., Snook, D., Courtenay-Luck N., Dhokia, B., Krausz, T., Lambert, H.E., Munro, A.J., McWhinney, N., Taylor-Papadimitriou, J., Durbin, H., and Bodmer W.F., 1986, Phase I clinical trial of intraperitoneally administered radiolabelled monoclonal antibodies in the treatment of advanced ovarian cancer (In press).Google Scholar
  10. Hammersmith Oncology Group and Imperial Cancer Research Fund, 1984, Antibody guided irradiation of malignant lesions: three cases illustrating a new method of treatment, Lancet, i.:1441.Google Scholar
  11. Halpern, S.E., Hagan, P.L., Bartholomew, R.M., Frincke, J.M., Poggenburg, J.K., Merchant, E.B., and Carlo, D.J., 1986, Kinetics and distribution of subcutaneously administrated of In-111 IgG and IgM antibodies (A) in a mouse model, J. Nucl. Med., 27:902.Google Scholar
  12. Paganelli, G., Riva, P., Moscatelli, G., Stecchiotti, A., Agostini, M., Landi, G., Tison, V., Panacea, P., and Siccardi, A.G., 1986, Improved immunoscintigraphy by subcutaneous injection of 99m-Tc or 111-In labelled F(ab′)2 fragments of an anti-melanoma monoclonal antibody, Nucl. Med. Biol., 13:423.Google Scholar
  13. Riva, P., Paganelli, G., Cacciaguerra, G., Gentili, G., Marri, L., Tison, V., Marangolo, M., and Amadori, D., 1985a, Antibody guided tumour detection using 131-I labelled F(ab′)2 fragments of an anti-CEA MoAb, Br. J. Cancer, 52:649.Google Scholar
  14. Riva, P., Paganelli, G., Amadori, D., Marangolo, M., Gambi, G., Cacciaguerra, G., Tison, V., Panacea, P., Moscatelli, G., Fiorentini, G.M., and Gentili, G., 1985b, Radio immunodetection of primary and metastatic tumor of g.i. tract by means of I-131 or In-111 labelled F(ab′)2 anti-CEA, administered by intravenous or intraperitoneal route, in: “Nuklearmedizin”, H.A.E. Schmidt, P.J. Ell, and K.E. Britton, eds., Schattauer Verlag, Stuttgart.Google Scholar
  15. Riva, P., Paganelli, G., Tison, V., Cacciaguerra, G., Gambi, G., Fiorentini, G.M., Panacea, P., and Gentili, G., 1986a, Antibody guided tumour detection in patients with gastrointestinal cancer after intravenous and/or intraperitoneal administration of radiolabelled monoclonal antibodies, Ital. J. Gastroenterol., 18:52.Google Scholar
  16. Riva, P., Paganelli, G., Amadori, D., Tison, T., Marangolo, M., Cacciaguerra, G., Fiorentini, G.M., Moscatelli, G., Panacea, P., Riceputi, G. and Gentili, G., 1986b, Loco-regional administration of monoclonal antibodies: a way to improve the antibody concentration in tumour, in: “International Symposium on Monoclonals and DNA Probes in Diagnostic and Preventive Medicine,” Raven Press, New York.Google Scholar
  17. Siccardi, A.G., Buraggi, G.L., Callegaro, L., Mariani, G., Natali, P.G., Abbati, A., Bestagno, M., Caputo, V., Galli, G., Mansi, L., Masi, R., Paganelli, G., Riva, P., Salvatore, M., Sanguined, M., Turco, G.L., Scassellati, G.A., and Ferrone, S., 1986, A Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies to patients with melanoma, Cancer Res., 46:4817.PubMedGoogle Scholar
  18. Wilson, B.S., Imai, K., Natali, P.G., and Ferrone, S., 1981, Distribution and molecular characterization of a cell surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies, Int. J. Cancer, 28:293, 1981.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Pietro Riva
    • 1
  1. 1.Reparto di Medicina NucleareOspedale M. BufaliniCesenaItaly

Personalised recommendations